RxDoctor Payments Data

Tim Chowdhury, MD

Interventional Pain Medicine · Dublin, OHNPI 1154491611

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $1,260 of the $2,072 with a category attached, or 60.8%. Medtronic accounts for 71.0% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2019 at $1,533 and has fallen 92.9% since, to $108 in 2025. That places this record below the midpoint for interventional pain medicine clinicians in OH, where the typical reported total is $5,193.

$2,072in general payments, 2019–2025

Across 33 payments — averaging $62.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$1K
  • Curonix LLC$205
  • Collegium Pharmaceutical, Inc.$121
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$99
  • Stimwave Technologies Incorporated$95
  • Pfizer$55
  • plus $27 from 2 others

What the payments were for

  • Travel & lodging$1,26061%
  • Food & beverage$81139%

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,072 in reported general payments places this provider in the 25th percentile of 67 interventional pain medicine providers in Ohio.

See all interventional pain medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$55,511
Medicare patients
27
Services billed
541

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MovantikNaloxegol Oxalate45$18,590
Nucynta ErTapentadol Hcl11$13,302
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen447$10,447
Gabapentin389$3,603
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen186$3,354
Methadone Hcl218$3,099
Pregabalin115$2,756
Tizanidine Hcl227$2,066
Celecoxib33$1,760
Lidocaine23$1,709
Morphine Sulfate ErMorphine Sulfate80$1,447
Diclofenac Sodium38$1,030
Tramadol Hcl80$799
Morphine Sulfate12$409
Ibuprofen72$361

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Nucynta Er$121$13,30211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 67 interventional pain medicine providers in Ohio.

Other interventional pain medicine in Dublin

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →